Physician profile
Valarie Mitchell
NPI 1164448981
$5,258.61
in general payments reported to CMS, 2019-2025
58 companies · $1,189 in 2025
The $1,189 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $693 · 2022: $739 · 2023: $1,228 · 2024: $1,410 · 2025: $1,189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,727 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,726.65 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $653.08 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Eisai INC. | $372.13 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $324.13 | 2021-2025 | Kisqali |
| Astrazeneca Pharmaceuticals Lp | $320.18 | 2021-2025 | Lynparza, Imfinzi, Enhertu |
| Glaxosmithkline, LLC. | $313.28 | 2021-2025 | Zejula, Jemperli |
| Takeda Pharmaceuticals U.S.A., INC. | $284.53 | 2023-2025 | Ninlaro, Iclusig |
| Beigene USA, INC. | $239.76 | 2021-2025 | Brukinsa, Tevimbra |
| Janssen Biotech, INC. | $227.63 | 2021-2025 | Rybrevant, Imbruvica, Erleada |
| Adaptive Biotechnologies Corporation | $203.93 | 2023-2025 | Clonoseq |
| Daiichi Sankyo INC. | $155.24 | 2022-2025 | Enhertu, Injectafer |
| Incyte Corporation | $152.86 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Astellas Pharma US INC | $148.79 | 2021-2025 | Veozah |
| Pharmacyclics LLC, An Abbvie Company | $137.48 | 2021-2023 | Imbruvica |
| Gilead Sciences, INC. | $129.81 | 2023-2025 | Trodelvy |
| Lilly USA, LLC | $120.30 | 2021-2025 | Jaypirca, Verzenio |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Valarie Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.